Your browser doesn't support javascript.
loading
Ether lipid biosynthesis promotes lifespan extension and enables diverse pro-longevity paradigms in Caenorhabditis elegans.
Cedillo, Lucydalila; Ahsan, Fasih M; Li, Sainan; Stuhr, Nicole L; Zhou, Yifei; Zhang, Yuyao; Adedoja, Adebanjo; Murphy, Luke M; Yerevanian, Armen; Emans, Sinclair; Dao, Khoi; Li, Zhaozhi; Peterson, Nicholas D; Watrous, Jeramie; Jain, Mohit; Das, Sudeshna; Pukkila-Worley, Read; Curran, Sean P; Soukas, Alexander A.
Afiliación
  • Cedillo L; Center for Genomic Medicine and Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, United States.
  • Ahsan FM; Broad Institute of Harvard and MIT, Cambridge, United States.
  • Li S; Program in Biological and Biomedical Sciences, Division of Medical Sciences, Harvard Medical School, Boston, United States.
  • Stuhr NL; Center for Genomic Medicine and Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, United States.
  • Zhou Y; Broad Institute of Harvard and MIT, Cambridge, United States.
  • Zhang Y; Program in Biological and Biomedical Sciences, Division of Medical Sciences, Harvard Medical School, Boston, United States.
  • Adedoja A; Center for Genomic Medicine and Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, United States.
  • Murphy LM; Broad Institute of Harvard and MIT, Cambridge, United States.
  • Yerevanian A; Leonard Davis School of Gerontology, University of Southern California, Los Angeles, United States.
  • Emans S; Center for Genomic Medicine and Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, United States.
  • Dao K; Broad Institute of Harvard and MIT, Cambridge, United States.
  • Li Z; Center for Genomic Medicine and Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, United States.
  • Peterson ND; Broad Institute of Harvard and MIT, Cambridge, United States.
  • Watrous J; Center for Genomic Medicine and Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, United States.
  • Jain M; Broad Institute of Harvard and MIT, Cambridge, United States.
  • Das S; Program in Biological and Biomedical Sciences, Division of Medical Sciences, Harvard Medical School, Boston, United States.
  • Pukkila-Worley R; Center for Genomic Medicine and Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, United States.
  • Curran SP; Broad Institute of Harvard and MIT, Cambridge, United States.
  • Soukas AA; Program in Biological and Biomedical Sciences, Division of Medical Sciences, Harvard Medical School, Boston, United States.
Elife ; 122023 08 22.
Article en En | MEDLINE | ID: mdl-37606250
Metformin is the drug most prescribed to treat type 2 diabetes around the world and has been in clinical use since 1950. The drug belongs to a family of compounds known as biguanides which reduce blood sugar, making them an effective treatment against type 2 diabetes. More recently, biguanides have been found to have other health benefits, including limiting the growth of various cancer cells and improving the lifespan and long-term health of several model organisms. Epidemiologic studies also suggest that metformin may increase the lifespan of humans and reduce the incidence of age-related illnesses such as cardiovascular disease, cancer and dementia. Given the safety and effectiveness of metformin, understanding how it exerts these desirable effects may allow scientists to discover new mechanisms to promote healthy aging. The roundworm Caenorhabditis elegans is an ideal organism for studying the lifespan-extending effects of metformin. It has an average lifespan of two weeks, a genome that is relatively easy to manipulate, and a transparent body that enables scientists to observe cellular and molecular events in living worms. To discover the genes that enable metformin's lifespan-extending properties, Cedillo, Ahsan et al. systematically switched off the expression of about 1,000 genes involved in C. elegans metabolism. They then screened for genes which impaired the action of biguanides when inactivated. This ultimately led to the identification of a set of genes involved in promoting a longer lifespan. Cedillo, Ahsan et al. then evaluated how these genes impacted other well-described pathways involved in longevity and stress responses. The analysis indicated that a biguanide drug called phenformin (which is similar to metformin) increases the synthesis of ether lipids, a class of fats that are critical components of cellular membranes. Indeed, genetically mutating the three major enzymes required for ether lipid production stopped the biguanide from extending the worms' lifespans. Critically, inactivating these genes also prevented lifespan extension through other known strategies, such as dietary restriction and inhibiting the cellular organelle responsible for producing energy. Cedillo, Ahsan et al. also showed that increasing ether lipid production alters the activity of a well-known longevity and stress response factor called SKN-1, and this change alone is enough to extend the lifespan of worms. These findings suggest that promoting the production of ether lipids could lead to healthier aging. However, further studies, including clinical trials, will be required to determine whether this is a viable approach to promote longevity and health in humans.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Metformina / Antimaláricos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Elife Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Metformina / Antimaláricos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Elife Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido